Oxilio NXP-001 formulation development contract

RNS Number : 9494A

Nuformix PLC

08 February 2022

 

REACH

8 February 2022

Nuformix plc

("Nuformix" or the "Company")

Oxilio signs a significant service contract with Quotient Sciences to support the formulation development of NXP-001

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that following the Company's signing of an exclusive global licensing agreement with Oxilio Ltd ("Oxilio") for NXP001 on 13 September 2021, Oxilio has progressed the product and signed a significant service contract with Quotient Sciences Ltd ("Quotient Sciences") to support the formulation development of NXP001. NXP001 is a proprietary new form of aprepitant which is currently marketed for cancer chemotherapy induced nausea and vomiting ("CINV").

Under the contract Oxilio will work with Quotient Sciences, a drug development and manufacturing accelerator, to identify and evaluate the cocrystal formulation of aprepitant to deliver optimal bioavailability for the treatment of CINV.

Quotient has prior experience of working with the Nuformix NXP-001 co-crystal and previously developed a capsule and a powder for oral suspension formulation, evaluating its performance in a relative bioavailability study versus EMEND (a branded aprepitant).

Quotient will prepare for Oxilio CMC (chemistry, manufacturing and controls) batches and stability data to support a clinical trial application for the new formulation of NXP001.

The Company looks forward to providing further updates on Oxilio's progress with NXP001 in due course.

Commenting, Alastair Riddell, Executive Chairman of Nuformix, said: "We are very pleased to see the progress Oxilio is making with NXP001.  Under the exclusive licence we signed with Oxilio we received an upfront payment, expect to receive milestone payments when the product completes clinical trials and ultimately royalties on any sales.  This arrangement is allowing Oxilio to progress NXP001 without cost to the Company whilst we focus on progressing our two lead assets, NXP002 and NXP004.  In relation to NXP002 and NXP004 we continue to make significant progress and I look forward to making further announcements in due course."

Enquiries:

Nuformix plc
Dr Alastair Riddell, Executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.

 

END

 

 

NRAEANAXEFSAEFA